All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Research on the Efficacy of Anlotinib in Treating Advanced Metastatic Colorectal Cancer

Author(s): Faliang Zhang and Jinpeng Qiao*
Department of Oncology, Shanghai Mengchao Cancer Hospital, Xuhui, Shanghai 201805, 1Department of Oncology, Wuxi No.2 People’s Hospital (Jiangnan University Medical Center), Wuxi, Jiangsu 214000, 2The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China

Correspondence Address:
Jinpeng Qiao, Department of Oncology, Wuxi No.2 People’s Hospital (Jiangnan University Medical Center), Wuxi, Jiangsu 214000, China, E-mail:

This research aims to comprehensively evaluate the safety and efficacy of anlotinib, and quantify its treatment effect in advanced metastatic colorectal cancer patients. 150 advanced metastatic colorectal cancer patients received third-line or more treatment in the oncology department of a tertiary hospital from January 2019 till January 2022. Their clinical data were collected and retrospectively analyzed. We evaluated the efficacy and adverse reactions of anlotinib. The objective remission rate of patients was 10 %, while the disease control rate was 64 %. The median progression-free survival time was 4.1 mo. It is revealed that liver metastasis and eastern cooperative oncology group score were related to progressionfree survival by univariate analysis. It is showed by multivariate analysis that liver metastasis was an independent factor that influencing the treatment of advanced metastatic colorectal cancer (p<0.05). Hypertension, fatigue, nausea and vomiting, albuminuria, and hypothyroidism were the relatively high incidences of complications caused by anlotinib. Anlotinib as the third line and above treatment is both effective and safe in treating advanced metastatic colorectal cancer.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report